Clinical Trials Update: June 2, 2005
Skin Cancer Common Cold Myasthenia Gravis Generalized
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
This trial will study STA-4783, a taxane potentiator that enhances the antitumor response of paclitaxel. Participants must be male or female 18 years of age or older with histologically confirmed metastatic (Stage IV) melanoma, and must be willing to sign a written informed consent document. Research sites located in Connecticut, Missouri and Alabama.
UVA Health System Department of Otolaryngology seeks adults with a new cold for a cold study. Participants must have a very runny nose. Study requires an overnight stay in a local hotel. Compensation is $200. Research site located in Charlottesville, Va.
Myasthenia Gravis Generalized
The efficacy and safety of CellCept will be assessed in patients with myasthenia gravis receiving prednisone, or other corticosteroids. During the study, patients will undergo gradual corticosteroid dose reduction, if they respond to treatment. Qualified participants will be adults 18 to 80 with a diagnosis of myasthenia gravis and a history of myasthenia weakness involving more than ocular (eye) or peri-ocular muscle. Research sites located throughout the United States, Germany, Czech Republic, Canada, Israel, Netherlands, Ukraine, and Great Britain.
Copyright 2005 CenterWatch. All rights reserved.